HIMS Leadership Just Pulled Off the Greatest Corporate Bear Trap in Modern Healthcare History 🚀🐻
# TL;DR: HIMS management intentionally sandbagged their Q4 earnings guidance to crash the stock to $13.74, authorized a $250M buyback to scoop up shares on the cheap, let the market price in a Novo Nordisk regulatory death knell, and then dropped a nuclear bomb on Friday: They settled the lawsuit with Novo Nordisk and are partnering to sell Wegovy. This isn't a memestock play; this is a multi-billion dollar valuation arbitrage engineered by a CEO who just outplayed Wall Street.
Alright, listen up. Forget the float mechanics. Forget the technicals. This is about pure corporate chess, and the CEO of Hims & Hers (HIMS) just mated Wall Street in three moves. Over the last two weeks, we just witnessed the greatest, legal, fundamental "Bear Trap" in modern healthcare history. Here is the exact timeline of how HIMS leadership orchestrated a scenario to flush out non-believers, buy back their own company at a 40% discount, and completely eliminate the single largest existential threat to their business model over a single weekend.
# Step 1: The Bait (Late February Earnings)
HIMS drops their Q4 earnings. The revenue is incredible ($2.35B, up 59% YoY), but management gets on the call and purposefully sounds depressing. They guide Q1 revenue flat/down, and announce they are spending $300M in CapEx to build sterile compounding factories.
* **The Reaction:** Wall Street algos and boomers freak out. JP Morgan literally dumps 14 million shares in a single week. The stock crashes from $25 to a 52-week low of $13.74.
* **The Trap is Set:** The market smells blood in the water. Analysts look at the pending Novo Nordisk lawsuit (the maker of Ozempic suing HIMS for compounding) and decide the FDA is going to shut HIMS down. The market prices the stock like the company is going bankrupt in 12 months.
# Step 2: The Vacuum (The $250M Buyback)
What didn't make the headlines during the earnings crash? On that exact same earnings call, HIMS quietly authorised a brand new **$250 Million Share Repurchase Program**. While JPM and retail were panic selling in the $14s, HIMS had hundreds of millions in pure cash ready to buy back their own company at a massive discount to fair value. They let the market tank the price, and they used their own treasury to accumulate equity. Every share they bought back was permanently retired, increasing the EPS value of every remaining share.
# Step 3: The Trap Door (Friday After-Hours)
Fast forward to Friday, March 6th. The market has priced HIMS for total regulatory destruction. Everyone believes the FDA or Novo Nordisk is going to crush them. Then, the nuke drops: **HIMS and Novo Nordisk have agreed to settle the lawsuit and partner up.** Read that again. The company trying to sue them out of existence just agreed to let them distribute Wegovy *through* the Hims & Hers platform. Official PR expected Monday. Oh, and while they were at it, HIMS just bought the massive international telehealth company Eucalyptus for $1.15 Billion, instantly giving them global scale and adding nearly half a billion in recurring revenue.
# The Reality for Monday
This isn't about hoping for a squeeze. This is about a company that was priced for bankruptcy on Thursday, suddenly having:
1. **Zero Regulatory Overhang:** The Novo Nordisk lawsuit is dead. They are now an official partner.
2. **Massive M&A Growth:** The Eucalyptus deal expands their total addressable market globally.
3. **A Compressed Float:** They just spent the last two weeks buying back their own stock at 52-week lows. The entire bearish thesis on this company is permanently dead. They sandbagged the market, bought the dip on their own stock, and eliminated their biggest rival by turning them into a supplier. I am holding 687 shares in an ISA at a $16.83 average. I'm not selling a single share under $30, because the fundamentals of this company have just entirely re-rated to the upside. See you at the open. 🚀🏥